CVS Health To Cover Humira Biosimilars April 1
04 January 2024 - 9:59AM
Dow Jones News
By Ben Glickman
CVS Health's pharmacy benefit management unit will add Humira
biosimilars to its covered drug lists starting April 1.
The Woonsocket, R.I.-based pharmacy and healthcare giant said
Wednesday that the AbbVie-made autoimmune-disease treatment Humira
would be removed from CVS Caremark's national commercial template
formularies, or the lists which determine prescription drug
coverage by health plans.
The company said Humira would still be an option for customers
with Choice and Standard Opt Out commercial formularies.
Biosimilars are drugs and treatment with no clinically
meaningful difference from branded alternatives.
CVS said that AbbVie had agreed to supply a committed volume of
co-branded Humira to CVS subsidiary Cordavis. The business was
launched in August with a focus on making biosimilar products.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 03, 2024 17:44 ET (22:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
CVS Health (NYSE:CVS)
Historical Stock Chart
From Nov 2024 to Dec 2024
CVS Health (NYSE:CVS)
Historical Stock Chart
From Dec 2023 to Dec 2024
